[Effects of hRAMP1 modified mesenchymal stem cells on restenosis and heart function in rabbit model of carotid angioplasty and myocardial infarction].
To observe the effects of mesenchymal stem cells (MSC) modified by human receptor activity-modifying protein 1 (hRAMP1) on restenosis and cardiac function post-myocardial infarction (MI) and explore the therapeutic safety for gene modification of MSC. The double-injury rabbit model with MI reperfusion and sacculus damaged atherosclerotic carotid were established according to the previous study. MSC were transfected with adenovirus vector with enhanced green fluorescence protein (EGFP) and then introduced into rabbit model. The animals were randomly divided into Ad-EGFP-hRAMP1-MSC transfection group (hRAMP1-MSC group, n = 24) and Ad-EGFP-MSC transfection group (MSC group, n = 24), and PBS transfection group (C group, n = 24). At Day 28 post-transplantation, the injured carotid arteries and infarction myocardium were harvested to detect the expression of EGFP-positive MSC and assess organization morphology by hematoxylin and eosin, triphenyltetrazolium chloride or immunohistochemical stains and heart function by echocardiography. On flow cytometry, most cells expressed CD29 and CD90 while few ones expressed CD45. MSC with EGFP and a continuous expression of CD31 were found in intima of damaged carotid of both hRAMP1-MSC and MSC, but the expression of EGFP was not found in the control group. At Day 28 post-transplantation, the improvement of heart function and the decrease of infarct size were found in the hRAMP1-MSC and MSC groups compared with that in the control group(EF: 60.6% ± 1.5%,50.8% ± 3.2% vs 38.2% ± 2.0%, infarct size: 20.7% ± 1.4%, 33.2% ± 3.7% vs 35.6% ± 2.7%, all P < 0.05), especially much higher in hRAMP1-MSC group. At Day 28 post-transplantation, the area of intima hyperplasia and the rate of neointima and media in the hRAMP1-MSC group were lower than those in the MSC and C groups (0.15 ± 0.05 and 0.33 ± 0.08 vs 0.77 ± 0.11, 0.24 ± 0.07 and 0.51 ± 0.11 vs 1.09 ± 0.23, all P < 0.05). Also the expression of α-SMA was found in the hyperplasia intima. The expression of proliferating cell nuclear antigen significantly decreased in the hRAMP1-MSC group than those of the MSC and control groups (0.120 ± 0.028 vs 0.366 ± 0.013 and 0.627 ± 0.049, both P < 0.05). And it was much lower in the MSC group than that in the control group. Compared with MSC alone, hRAMP1-modified MSC have the potency not only of more improvement on cardiac function and the recovery of damaged endothelium, but also of significant inhibition of the proliferation of vascular smooth muscle cells. The recombinant hRAMP1 adenovirus vectors do not affect the differentiation potential MSC into endothelial cells.